NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the results of a data-driven analysis conducted in collaboration with TransCelerate BioPharma Inc. (“TransCelerate”), which assesses the value of source document verification (SDV) in a risk-based approach to clinical trial site monitoring. Published in the November edition of the Drug Information Association’s Therapeutic Innovation & Regulatory Science (TIRS) journal, the results of the analysis support the TransCelerate-proposed methodology for risk-based monitoring (RBM), which can be adopted for different types, phases and stages of clinical trials.
Help employers find you! Check out all the jobs and post your resume.
